Imagine a skincare gel advertised to “soothe dry skin.” Now imagine the same gel promoted as “treating eczema.” The formula may be unchanged, but the second claim points to a medical purpose. That difference can affect which rules apply, what evidence is expected and whether the product needs a different regulatory route.
This is why deciding whether something is a medical device, cosmetic or medicine involves more than looking at its ingredients or packaging. Regulators may consider what the product is intended to do, how it works and how the manufacturer presents it—including claims made on websites and in advertising. The details vary between markets, so a classification that applies in one country should not automatically be assumed to apply in another. See MHRA guidance on borderline medicines and MHRA guidance on medical devices.
In this guide, we’ll look at the differences between these categories, show how claims can move a product toward a regulatory boundary and outline practical checks businesses can make before launch.
At a glance: how the three categories differ
This table is a starting point, not a substitute for market-specific assessment. For example, in the United States a product can meet the definitions of both a cosmetic and a drug when it has more than one intended use. See the FDA explanation of cosmetics, drugs and products that qualify as both.
What counts as a cosmetic?
In the EU, a cosmetic product is generally intended to come into contact with external parts of the body, teeth or oral mucosa, with purposes such as cleaning, perfuming, changing appearance, protecting, keeping in good condition or correcting body odour. The intended purpose matters: a product applied to the skin is not automatically a cosmetic if it is presented for a medical purpose. See Regulation (EC) No 1223/2009.
Typical cosmetic claims may describe:
- Cleansing or removing makeup
- Moisturising dry skin
- Improving the appearance of fine lines
- Adding fragrance
- Helping protect the skin from environmental dryness
- Making hair look smoother or shinier
The wording and overall presentation matter. A claim about the appearance of a feature is not necessarily the same as a claim to treat an underlying medical condition. But a single phrase does not decide classification in every country; regulators may assess the product’s complete presentation and intended use.
Example: “Helps skin look more hydrated” signals an appearance or condition-of-skin benefit. “Treats dermatitis” makes a disease-treatment claim and may lead to a different regulatory assessment.
When does a product become a medicine?
A product may be regulated as a medicine when it is presented as treating or preventing disease, or when its intended use and action meet a market’s legal definition of a medicinal product. In the UK, the MHRA describes borderline decisions as taking account of claims and mode of action. In the US, the FDA’s drug definition includes products intended to diagnose, cure, mitigate, treat or prevent disease, as well as certain products intended to affect the body’s structure or function. See MHRA guidance and the FDA overview.
Claims that may raise a medicinal-product question include:
- “Treats eczema”
- “Prevents fungal infection”
- “Relieves arthritis pain”
- “Stops hair loss”
- “Reduces inflammation”
- “Diagnoses a skin condition”
These examples are prompts for assessment, not a universal list of prohibited words. The regulatory meaning depends on context and local law. For instance, a claim about reducing the appearance of redness may be understood differently from a claim to treat inflammation.
A product’s ingredients can also matter. Regulators may consider whether a substance has a known therapeutic use, alongside the claims and presentation. So changing the copy alone may not resolve a classification question if the product’s composition or intended action points in another direction. See the FDA guidance on how intended use is established.
When is a product a medical device?
A medical device has a medical intended purpose. Depending on the market and applicable definition, that purpose may include diagnosing, preventing, monitoring, treating or alleviating disease or injury.
A key distinction between a medicine and a device is often how the product achieves its principal intended action. Under UK guidance, a device’s principal action must primarily be achieved by physical or mechanical means; it must not act principally through pharmacological, immunological or metabolic means, although an ancillary action may be permitted. See MHRA guidance on medical devices.
Examples to consider:
- A dressing intended to protect a wound may be assessed as a medical device.
- A cream promoted to treat a disease may raise a medicinal-product question.
- A diagnostic test intended to provide medical information may be a medical device or IVD, depending on the product and market.
- Software intended to support diagnosis or treatment may fall within medical device rules; general record-storage software may be treated differently. See MHRA guidance on software and other borderline products.
These are illustrative examples. A product’s name, physical form or sales channel does not settle its status by itself.
How can a product claim affect classification?
A product claim helps communicate what the manufacturer intends the product to do. Regulators may review the overall impression created by that communication, rather than looking at one label phrase in isolation.
That impression can be created by:
- Product name and label
- Instructions for use
- Website copy and product pages
- Packaging and promotional literature
- Advertisements and social media
- Testimonials or endorsements repeated in marketing
- Images, diagrams and before-and-after comparisons
UK guidance specifically says that medical-device assessments can consider explicit and implicit claims, the product’s mode of action, and how it is presented in promotional material and advertisements, including on websites. It also states that a general disclaimer is not acceptable if medical claims appear elsewhere in product materials. See MHRA guidance on medical-device classification and its borderline-products guidance.
In practice: a “not a medical device” disclaimer may not solve a problem if the rest of the product page promises to diagnose, treat or prevent a condition.
A claim can create a dual-purpose product
Some products have more than one intended use. The FDA gives anti-dandruff shampoo as an example: cleansing the hair is a cosmetic use, while treating dandruff is a drug use. In the US, that can mean the product is subject to requirements for both categories. See the FDA explanation of products that qualify as both.
This is a useful reminder for teams writing claims: a product does not always fit neatly into one category just because it is sold in a particular aisle or described as a “beauty” product.
Claim examples: how small wording changes can matter
The examples below show why teams should review the meaning of the claim, not just the product’s ingredient list. They are not classification decisions.
The final two examples illustrate why intended use, claims and function should be reviewed together. For products with a medical purpose, the technical function and the way results are communicated can both be relevant to classification.
Why a disclaimer or “cosmeceutical” label may not settle the issue
“Cosmeceutical” is a common marketing term, but the FDA says it is not a category defined under US law. A product is assessed according to the applicable legal definitions and its intended use—not simply the term chosen by the brand. See the FDA’s explanation of “cosmeceuticals”.
Likewise, disclaimers may not outweigh treatment or diagnosis claims elsewhere in the product’s presentation. In the UK, the MHRA says classification decisions can take account of explicit and implicit claims, how the product works and how it is promoted. See MHRA guidance.
A practical review should therefore look across the full set of materials, not only the pack label.
Why classification differs by country
Product categories and regulatory procedures are defined by local laws. Authorities may use different legal tests, terminology or evidence requirements, and some products sit at a boundary between categories.
For example:
- The UK’s MHRA describes medicine-device decisions as involving both claims and mode of action. See MHRA medicine guidance and MHRA device guidance.
- The FDA explains that a product may be a cosmetic, a drug or both, depending on intended use. See FDA guidance.
- Health Canada says that, for products at the cosmetic-drug interface, it considers factors including representations made about the product and its composition, with intended purpose taking precedence. See Health Canada’s classification guidance.
- India’s CDSCO states that products with a drug claim do not fall within the definition of a cosmetic for registration as a cosmetic. See CDSCO’s cosmetics FAQ.
These examples show why a classification conclusion for one market should not simply be copied into another market’s launch plan.
A practical pre-launch claims review
Before finalising product claims, bring regulatory, product, clinical, marketing and commercial teams into the same review. Use these questions to spot issues early:
- What is the product’s intended purpose? Write a clear, consistent intended-use statement.
- What does the product do, and how? Document the product’s principal mode of action.
- What does every claim imply? Review the label, website, ads, social posts, testimonials and visual content.
- Could a claim imply disease diagnosis, treatment or prevention? Flag therapeutic or diagnostic language for regulatory review.
- Do the claims match the evidence? Check that the level of evidence supports the exact wording and intended population.
- Have you assessed each target market separately? Confirm whether the same claim and regulatory route work in each jurisdiction.
- Is the product category reflected in the launch plan? Classification can affect registration or conformity steps, documentation, evidence, labelling and market access.
This review is particularly useful before packaging and advertising are locked. If a classification concern appears late, the business may need to revisit claims, evidence, timelines or market-entry plans.
Common claim-review mistakes
- Treating the ingredient list as the only factor
- Assuming that a product’s category in one country applies everywhere
- Using disease-treatment language on a product planned as a cosmetic
- Making stronger claims in online ads than on the label
- Reposting testimonials that imply a medical benefit
- Adding a disclaimer while leaving contradictory claims elsewhere
- Using “natural,” “wellness” or “cosmeceutical” as if those terms settle regulatory status
Each can create a mismatch between the product’s planned regulatory route and the way it is presented to customers.
How OMC Medical can help
When a product sits between cosmetic, medicine and medical device definitions, early classification work can help a business understand the questions to resolve before committing to market-specific claims and launch plans. OMC Medical supports regulatory strategy and product-registration work across markets, including assessment of intended purpose, claims and applicable market requirements.
Planning a product launch in multiple markets? Contact OMC Medical to discuss the product, its proposed claims and the target countries. A market-by-market assessment can help your team identify classification questions before finalising its regulatory and commercial plans.
Frequently asked questions
Do product claims determine whether something is a medical device, cosmetic or medicine?
Claims can be an important part of the assessment because they communicate the product’s intended purpose. Regulators may also consider how the product works, its composition and its overall presentation. The exact test varies by jurisdiction. See MHRA medicine guidance, MHRA device guidance and Health Canada’s classification guidance.
Can the same product be both a cosmetic and a medicine?
In the US, yes. The FDA explains that a product can be both where it has separate cosmetic and drug intended uses—for example, an anti-dandruff shampoo that cleanses hair and treats dandruff. Other markets may apply different rules. See the FDA’s overview.
Does calling a product “cosmeceutical” define its regulatory category?
No. The FDA says “cosmeceutical” is not a category defined under US law. Businesses should assess the product against the definitions and requirements in each market where they plan to sell it. See the FDA explanation.
Can a disclaimer cancel out a medical claim?
Not necessarily. UK guidance says a general disclaimer may not be acceptable when medical claims are made or implied elsewhere in product labelling or promotional material. See the MHRA borderline-products guidance.
Should a company use the same product claims in every country?
Not without checking. Regulatory definitions and procedures can differ. Review the intended purpose, claims and applicable route in every target market before launch.
